Promocard

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Promocard

Property Description
Active ingredient Isosorbide Mononitrate (INN)
Form Oral tablets (Immediate-release and Extended-release)
Pharmacological class Vasodilator / Nitrate drug
General purpose Prophylactic cardiovascular support
Origin Synthetic compound (Organic nitrate ester)

What is Promocard and Its Pharmacological Classification?

Promocard is a prescription-only medicine containing the active substance Isosorbide Mononitrate, which is medically classified as an Antianginal agent and a Vasodilator belonging to the nitrate drug class. Isosorbide Mononitrate is a synthetic compound used in the long-term management of certain cardiovascular conditions.

As a foundational cardiovascular medicine, Promocard’s classification as a Vasodilator underscores its primary function of widening blood vessels. Isosorbide Mononitrate is an active metabolite that exhibits high oral bioavailability, making it well-suited for a sustained therapeutic effect. The use of this drug class for long-term support is widely clinically recognized for its role in maintaining stability in cardiology patients.

Composition, Origin, and Available Forms

The medication is a single-ingredient product, formulated for oral administration as solid tablets using standard inactive excipients as the base. The chemical core, Isosorbide Mononitrate, is an organic nitrate ester derived synthetically. The formulation is distinct because it offers preparations in both immediate-release and extended-release (or modified-release) forms.

The extended-release tablet is specifically engineered to ensure a gradual and prolonged delivery of the active compound over a longer period. This controlled release is designed to provide consistent support throughout the day, a key feature for prophylactic treatments. Its long-acting preparation status emphasizes its role in sustained, chronic care.

General Purpose and Action of Isosorbide Mononitrate

The general purpose of Promocard is to reduce the workload on the heart by easing blood flow, supporting overall anti-ischemic goals. It achieves this by acting as a Nitric oxide (NO) precursor, signaling the vascular smooth muscle to relax, leading to vasodilation. This process preferentially expands the veins, reducing the amount of blood returning to the heart (known as reduced preload), which is the cornerstone of its intended general antianginal purpose.

Regulatory References

  1. NIH MedlinePlus Isosorbide Mononitrate Information
  2. NIH NCBI Isosorbide Monograph

What side effects are possible with Promocard?

Possible Side Effects and Safety Information

The official safety information for Promocard (Isosorbide Mononitrate) focuses on adverse reactions related to its function as a vasodilator, classified by frequency and affected body systems, as documented by regulatory agencies.

Adverse Reaction Classification

Side effects are formally grouped into organ systems, with the most commonly reported reactions classified as follows:

  • Very Common (ge 10%): Headache.
  • Common (ge 1% to <10%): Dizziness, Light-headedness, Hypotension (low blood pressure), Flushing, Reflex Tachycardia, and Nausea.
  • Uncommon (ge 0.1% to <1%): Vomiting, Syncope (fainting), and Allergic Skin Reactions.

These effects are largely categorized under Nervous System Disorders (e.g., headache) and Vascular Disorders (e.g., hypotension).

Safety Patterns and Constraints

The regulatory profile highlights specific safety patterns related to exposure. The incidence of headache, the most frequent event, is noted to often diminish or disappear after the first one to three weeks of continuous therapy. Conversely, effects such as light-headedness and hypotension are commonly observed at the start of treatment or following a dosage increase.

Serious adverse reactions documented in official sources include cases of Severe Hypotension which may lead to collapse, and extremely rare occurrences of Methemoglobinemia.

Population-Specific Notes

The official labeling includes specific safety considerations for certain patient groups. Caution is advised for Older Adults due to an increased risk of severe and orthostatic hypotension. Furthermore, the safety and effectiveness of the medication have not been established for pediatric use.

Crucially, use with certain other vasodilating medicines, such as Phosphodiesterase Type 5 (PDE-5) Inhibitors, is officially restricted due to the potential for life-threatening severe hypotension.

Overdose and Emergency Response

An overdose of Promocard (Isosorbide Mononitrate) is associated with an exaggeration of its potent vasodilating effects, as documented in official regulatory sources. Severe overdose manifestations that require immediate medical attention include profound hypotension, severe throbbing headache, syncope (fainting), vertigo, confusion, and potentially seizures.

Official labeling states that a major overdose can lead to life-threatening outcomes such as circulatory collapse. A specific, serious toxic complication documented is Methemoglobinemia, characterized by cyanosis (bluish skin/lips) and impaired oxygen delivery. Methylene Blue is the specified treatment for this toxicity.

When an overdose is suspected, regulatory guidance mandates that you seek emergency medical attention and contact the Poison Help line. Treatment is symptomatic and supportive, focusing on managing the critically low blood pressure, often through intravenous fluid infusion. Continuous monitoring of blood pressure and pulse is required for at least 12 hours post-ingestion. Patients with pre-existing conditions like renal disease or congestive heart failure are noted to require special consideration for fluid management.

Therapeutic Uses of Promocard

What Promocard Treats: Main Uses and Benefits

Promocard (Isosorbide Mononitrate) is primarily used to provide long-term cardiovascular support for specific chronic conditions. It is indicated for the prevention and treatment of angina pectoris due to coronary artery disease. This medication is generally used to prevent or manage conditions marked by recurrent or episodic manifestations of chronic stable angina pectoris.

Supporting Symptom Control and Functional Stability

The goal of therapy is to help support the reduction of the frequency, severity, and duration of these predictable anginal episodes. The types of symptomatic manifestations addressed include chest pain, pressure, and tightness associated with acute or episodic changes. This approach helps ease the overall symptom burden, and supports general well-being during symptomatic phases. Promocard is generally relevant for individuals experiencing symptoms that interfere with daily functioning, assisting with maintaining functional stability in routine activities.


Quick Fact: Relief for Recurrent Chest Discomfort The long-term use of this medication is primarily for prophylactic support, assisting patients with maintaining functional stability and managing symptoms that interfere with daily comfort.

Regulatory References

  1. ISOSORBIDE MONONITRATE tablet - DailyMed - NIH

Eligibility and Restrictions for Use

Official Eligibility Status for Promocard

The drug name Promocard does not appear as a recognized medicinal product in the authoritative government regulatory databases of the United States (FDA), European Union (EMA), or other major global agencies. Consequently, there is no officially documented and universally accepted prescribing information—such as the FDA Prescribing Information or the EMA Summary of Product Characteristics (SmPC)—that defines the legal eligibility criteria for its use.

In the absence of an official regulatory label, specific patient populations who may use the medicine (the eligible population) and those who are prohibited from using it (contraindicated populations) cannot be formally stated. However, regulatory standards for any drug categorize eligibility based on the following general domains:

Eligibility Classification Official Regulatory Information Status
Populations for whom use is contraindicated Not established by official labeling
Age-related eligibility rules Not established by official labeling
Pregnancy and lactation status Not established by official labeling
Condition-specific restrictions Not established by official labeling

All medicines approved by regulatory bodies are required to explicitly list contraindications, which are conditions or patient characteristics that forbid the use of the drug due to unacceptable risk. These typically include documented hypersensitivity to any ingredient and specific serious co-morbidities. For Promocard, these critical constraints are not available in public regulatory records.

What should I know about interactions with other medicines?

Contraindicated Combinations

The co-administration of Promocard is strictly prohibited with specific medicinal products based on regulatory documentation. This formal restriction is due to the potential for a severe, life-threatening amplification of vasodilatory effects, which can result in profound hypotension, syncope, or myocardial ischemia. Products containing Phosphodiesterase Type-5 (PDE-5) Inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil) and the Soluble Guanylate Cyclase (sGC) Stimulator, Riociguat, are officially designated as contraindicated for co-use.

Documented Pharmacodynamic Effects

Additive effects are officially documented when Promocard is combined with other agents that reduce blood pressure. The hypotensive actions of other vasodilators, antihypertensives (such as beta-blockers and ACE inhibitors), and calcium channel blockers are potentiated. This combined effect can lead to the risk of marked symptomatic orthostatic hypotension.

Other Interaction Patterns

A specific exposure alteration is noted with Dihydroergotamine, where co-administration may increase its systemic blood level and enhance its hypertensive effect. Additionally, Alcohol exhibits additive vasodilatory properties, which may increase the risk of postural hypotension. The official prescribing information also notes that concomitant food intake decreases the rate of Promocard absorption but does not alter the total systemic exposure (AUC) to the medicine.

Mechanism of Action

Bioactivation and the Nitric Oxide Signaling Pathway

Promocard's action begins inside the vascular smooth muscle cells, where the active ingredient, Isosorbide Mononitrate, acts as a prodrug. It is bioactivated by cellular enzymes to release Nitric Oxide (NO), a gaseous molecule that acts as a biological messenger molecule. This released NO activates the enzyme Soluble Guanylyl Cyclase (sGC), which in turn elevates the concentration of cyclic Guanosine Monophosphate (cGMP). This molecular cascade initiates the process of vessel relaxation.


Modulation of Vascular Tone and Preload

The surge in cGMP signals the smooth muscle surrounding the blood vessels to relax, a process known as vasodilation. This effect is most pronounced in the venous capacitance vessels, causing them to dilate and increasing the pooling of blood away from the heart. By reducing the volume of blood returning to the heart, this mechanism results in lowered cardiac preload and decreased myocardial oxygen demand.


Mechanistic Limitations

The effectiveness of this mechanism can be physiologically constrained. Continuous, uninterrupted exposure can lead to a phenomenon called Nitrate Tolerance, where the target cells' responsiveness to the NO-cGMP signal diminishes. Furthermore, its requirement for cellular bioactivation results in a slow onset of action.

Dosage and Administration Information

How to Use Promocard: Official Administration Guidelines

Promocard, which contains Isosorbide Mononitrate, is a prescription medicine formulated for oral administration only. Official instructions for its use are structured to ensure a required daily period without the active compound present, which is essential to prevent the development of tolerance during long-term use.


Dosing and Scheduling

The required dosing schedule differs based on the formulation:

  • Immediate-Release (IR) Tablets: The standard maintenance dose is typically 20 mg taken twice daily. The two doses must be separated by a 7-hour interval (e.g., first dose upon waking and the second dose 7 hours later).
  • Extended-Release (ER) Tablets: The typical starting dose is 30 mg or 60 mg taken once daily. The dose may be increased up to 120 mg once daily as needed. The ER tablet is usually taken in the morning (upon arising) to ensure a sufficiently long daily nitrate-free period.

Administration Instructions

Feature Official Requirement
Preparation ER tablets must be swallowed whole; they must not be crushed, chewed, or split to protect the controlled-release mechanism. IR tablets may be taken with or without food.
Missed Dose If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped. Doses must not be doubled.
Population Routine dosage adjustment is generally not recommended for older adults or those with renal or hepatic impairment, though care may be exercised in the elderly or those with marked insufficiency.

The oral tablets are not intended for use in treating an acute episode, as the onset of action is not rapid enough for immediate relief.

Recent Clinical Evidence

Evidence for Use in Chronic Stable Angina Pectoris

Research involving Promocard (Isosorbide Mononitrate) has primarily examined evidence related to chronic stable angina pectoris, a condition characterized by fluctuating or episodic manifestations of chest discomfort due to coronary artery disease. The foundational evidence is derived from short-term, randomized controlled trials (RCTs) that compared the medicine to an inactive substance (placebo) or to other similar agents.

The main outcomes monitored in these trials were related to physical discomfort and the body's functional imbalance. Researchers examined changes in the frequency and severity of anginal episodes and the need for short-acting nitrate use. Studies monitored physiological strain by assessing changes in the ability to perform standardized exercise and patient-reported outcomes describing perceived discomfort.

Long-Term Studies and Durability of Effect

While many foundational studies focused on short-term data, research has explored the durability of the measured response over defined time intervals, monitoring patients over intermediate-term periods of up to six months. A key factor that research has highlighted is the issue of nitrate tolerance, where the measured antianginal response may attenuate with continuous use. Research describes patterns observed when specific dosing strategies were applied in an attempt to address the attenuation of response observed in the study setting.

Research in Specific Patient Groups

Research primarily examined adult populations with chronic stable angina, including those using the drug as an adjunctive treatment alongside other heart medications like beta-blockers. Studies also included older adults or geriatric patients. These studies contribute to the evidence for these patient groups, but comprehensive data for certain subgroups remain insufficient to determine if the findings are the same across all elderly patients.

What Remains Uncertain and Research Gaps

Evidence highlights that while the primary trials focused on symptom management, there is limited information for major long-term cardiac events, such as changes in overall survival. Another key area of uncertainty relates to the aforementioned attenuation of measured response and the "zero-hour effect," which is a possible lessening of the effect near the end of the daily dosing period. Comparative evidence that examines differences between Promocard and certain other established treatments is limited.

Key Studies & References

  1. Isosorbide Mononitrate Extended-Release Tablets, USP Rx only - Clinical Trials and Precautions
  2. [Changes in exercise capacity and in induced ischemia with an oral dose of 5 isosorbide mononitrate in patients with stable angina pectoris] (Example of early RCT design)

Frequently Asked Questions (FAQ)

Common questions about Promocard (FAQ)


Q: Is Promocard a blood pressure medicine or for heart rhythm?

Official information classifies the medicine as a Vasodilator and an Antianginal agent. Its main purpose is to prevent chest pain by relaxing blood vessels and decreasing the heart’s workload. It is not primarily categorized as a medication for heart rhythm disorders (antiarrhythmic).


Q: Can you take Promocard if you have kidney problems?

The active substance is eliminated primarily through the kidneys. While studies on some formulations suggest severe kidney impairment may not require a change, some official guidelines indicate that dose adjustments might be considered for patients with severe kidney impairment, particularly with certain formulations, to help prevent the accumulation of the medicine in the body.


Q: Is Promocard the same class of drug as other heart medications like [Similar Drug Name]?

According to official sources, the medicine belongs to the group of compounds known as nitrates or nitrovasodilators. It is derived from isosorbide dinitrate and produces similar effects to other organic nitrates in this class.


Q: Is it normal to feel a little dizzy when first starting Promocard?

Official safety data indicates that dizziness and lightheadedness are common side effects. These symptoms are most often reported when a person first begins treatment or when the dose is increased. In many cases, these initial effects tend to lessen or disappear with continued, long-term use.


Q: Can older adults generally tolerate Promocard well?

Official safety information advises caution for older adults due to the increased risk of severe and orthostatic hypotension (low blood pressure when changing posture). The need for careful monitoring may be greater, particularly if the individual also has severe kidney impairment.


Q: Is there a generic version of Promocard available?

The active ingredient in this medicine, Isosorbide Mononitrate, is available as a generic medication in many regions.


Q: Can Promocard be taken with common cholesterol-lowering medicines?

Specific interactions with common cholesterol-lowering medicines (such as statins) are generally not highlighted in regulatory warnings. It is important for patients to discuss all concurrent medicines, including cholesterol-lowering agents, with a healthcare provider.


Q: Do people on Promocard need special monitoring or blood tests?

Official safety information notes that monitoring of blood pressure and heart rate is typically performed during treatment. Due to the risk of severe hypotension and Methemoglobinemia, monitoring for related symptoms is an important part of care.


Q: Does taking Promocard mean I have to limit my caffeine intake?

Regulatory documents include explicit warnings about interactions with alcohol and certain other blood pressure-lowering medications. However, they do not formally specify limitations on caffeine intake.


Q: What if I accidentally take two doses of Promocard too close together?

Regulatory guidance emphasizes the importance of not doubling or taking extra doses. Symptoms of an overdose are typically related to exaggerated vasodilatory effects, such as very low blood pressure (profound hypotension) and fainting.


Q: Does Promocard interact badly with common over-the-counter pain relievers?

Regulatory interaction sections do not formally document specific negative interactions with common over-the-counter pain relievers, such as acetaminophen or ibuprofen. It is important for patients to disclose all over-the-counter medicines to a healthcare provider.


Q: Is it possible for Promocard to stop working after taking it for many years?

Studies and official information indicate that continuous, uninterrupted use can lead to nitrate tolerance, where the therapeutic effect of the medicine is diminished. The prescribed dosing schedule includes a daily nitrate-free interval to help minimize this risk.


Q: Is it safe to drink a moderate amount of alcohol while on Promocard?

Alcohol is formally documented to have additive vasodilatory properties with this medicine. This combination can increase the risk of low blood pressure (hypotension) and associated symptoms like dizziness when standing up.


Q: Can Promocard be crushed or split if swallowing is difficult?

Official administration instructions specify that the extended-release tablets are required to be swallowed whole and should not be altered (crushed, chewed, or split). This is necessary because altering the tablet destroys the controlled-release mechanism.


Q: How long does it usually take for side effects from Promocard to go away?

According to official safety information, the most common side effect, headache, often lessens or disappears after the first one to three weeks of continuous therapy. Other initial side effects, such as dizziness, may also disappear during long-term treatment.


Q: Can people with diabetes safely take Promocard?

Regulatory documents do not list specific warnings or contraindications related solely to diabetes. Due to the standard practice when beginning any cardiovascular medicine, blood glucose monitoring is generally part of the management plan for patients with diabetes.


Q: Are there any serious, but rare, side effects I should be aware of with Promocard?

Official sources document serious adverse reactions including cases of severe Hypotension (very low blood pressure) which may lead to collapse. Extremely rare occurrences of Methemoglobinemia (a blood disorder) have also been documented.


Q: Do children ever take Promocard, and is it safe for them?

Official prescribing information indicates that the safety and effectiveness of the medication have not been established for pediatric use. Pediatric dosing is not provided in the prescribing information.


Q: Is Promocard known to cause any issues with liver function?

The medicine is primarily metabolized by the liver. While routine dosage adjustment is often not recommended for mild impairment, caution may be advised in patients who have more significant liver insufficiency.


Q: Are there any herbs or supplements that definitely interact with Promocard?

Official guidelines recommend that patients discuss all of their concurrent use of over-the-counter medicines, vitamins, minerals, herbal products, and other supplements with a healthcare provider due to the potential for interactions.


Q: Can Promocard affect my sleep patterns?

Clinical trial data indicates that sleep disturbances have been reported during treatment with this medicine. However, in some studies, the frequency of these disturbances was reported as similar to the placebo group.


Q: Is Promocard safe to take during pregnancy or while breastfeeding?

There are no adequate and well-controlled studies of the medicine in pregnant women. Regulatory labeling indicates that the use of this medicine is generally reserved for situations where the potential benefit is judged to justify the potential risk to the fetus. It is also unknown if the medicine is excreted in human breast milk.


Q: Does Promocard interact with birth control pills?

No specific clinically significant interaction affecting the overall effectiveness of common hormonal birth control pills is typically listed in regulatory warnings. It is important to discuss all medications with a healthcare provider.


Q: Are there any known issues with taking Promocard before surgery?

It is necessary for patients to inform their doctor, surgeon, or dentist that they are taking this medicine before any surgical procedure. This is important because the medicine can interact with certain anesthetics to cause severely low blood pressure.


Q: What percentage of people experience the major side effects of Promocard?

Official safety information groups side effects by frequency. Very Common (ge 10% of users) is Headache. Common (ge 1% to <10% of users) includes Dizziness, Hypotension (low blood pressure), Flushing, and Nausea.


Q: What kind of improvements in my condition should I look for after a month on Promocard?

Clinical trials tracked improvements in the frequency and severity of anginal episodes (chest pain) and a reduction in the need to use short-acting nitrates. Researchers also monitored the patient's ability to perform standardized exercise.


Q: How long does it typically stay in your system?

The medicine has an elimination half-life of approximately 5 to 6 hours. For the extended-release formulation, the concentration in the blood is designed to drop significantly by the end of the daily dosing period, ensuring a necessary drug-free interval.


How should Promocard be stored and disposed of?

Storage and Disposal Requirements for Promocard

Promocard (Isosorbide Mononitrate) must be stored according to official regulatory guidelines to maintain its stability.


Official Storage Conditions

Requirement Regulatory Specification
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Keep the container tightly closed. Protect from light and moisture.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Promocard must be disposed of according to national and local regulations. The preferred method is returning the medicine via an official drug take-back program. If this is unavailable, the medicine should be mixed with an unappealing substance, placed in a sealed bag, and discarded with the household trash. The medication should not be poured down a drain or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Promocard found in:

A-Z Index: